Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Nizar M. Tannir

Oncology | Urology
MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 

Distinguished in WT1-Related Wilms Tumor Syndromes
MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nizar Tannir is an Oncologist and an Urologist in Houston, Texas. Dr. Tannir is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Neuroendocrine Tumor, Nephrectomy, and Orchiectomy.

His clinical research consists of co-authoring 292 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Urology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Hawaii Medical Assurance Association
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030
Call: 713-592-5433

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor
A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Everolimus, Lenvatinib
Study Phase: Phase 2
Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma
Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Doxorubicin Hydrochloride, Gemcitabine, Gemcitabine Hydrochloride, Ixazomib, Ixazomib Citrate
Study Phase: Phase 2
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: DFF332, RAD001, PDR001, NIR178
Study Phase: Phase 1
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy
Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Nivolumab, Sitravatinib
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
View 6 Less Clinical Trials

292 Total Publications

Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Journal: Urologic oncology
Published: May 12, 2025
View All 292 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jose A. Karam
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jose A. Karam
Urology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Jose Karam is an Urologist in Houston, Texas. Dr. Karam is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Upper Tract Urothelial Carcinoma (UTUC), Chromophobe Renal Cell Carcinoma, Nephrectomy, and Thrombectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Eric A. Jonasch
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Eric A. Jonasch
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jonasch is an Oncologist in Houston, Texas. Dr. Jonasch is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Hemangioblastoma, Chromophobe Renal Cell Carcinoma, Hypothalamic Hamartomas, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Surena F. Matin
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Surena F. Matin
Urology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Surena Matin is an Urologist in Houston, Texas. Dr. Matin is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Ureteroscopy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tannir's expertise for a condition
ConditionClose
  • Elite
  • Chromophobe Renal Cell Carcinoma
    Dr. Tannir is
    Elite
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Nephrectomy
    Dr. Tannir is
    Elite
    . Learn about Nephrectomy.
    See more Nephrectomy experts
  • Renal Cell Carcinoma (RCC)
    Dr. Tannir is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Tannir is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Clear Cell Sarcoma
    Dr. Tannir is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Tannir is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Neuroendocrine Tumor
    Dr. Tannir is
    Distinguished
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
  • Wilms Tumor
    Dr. Tannir is
    Distinguished
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
  • WT1-Related Wilms Tumor Syndromes
    Dr. Tannir is
    Distinguished
    . Learn about WT1-Related Wilms Tumor Syndromes.
    See more WT1-Related Wilms Tumor Syndromes experts
  • Advanced
  • Bone Tumor
    Dr. Tannir is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Melanoma
    Dr. Tannir is
    Advanced
    . Learn about Melanoma.
    See more Melanoma experts
  • Rhabdoid Tumor
    Dr. Tannir is
    Advanced
    . Learn about Rhabdoid Tumor.
    See more Rhabdoid Tumor experts
  • Experienced
  • Bladder Cancer
    Dr. Tannir is
    Experienced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Brain Tumor
    Dr. Tannir is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Ewing Sarcoma
    Dr. Tannir is
    Experienced
    . Learn about Ewing Sarcoma.
    See more Ewing Sarcoma experts
  • Laminectomy
    Dr. Tannir is
    Experienced
    . Learn about Laminectomy.
    See more Laminectomy experts
  • Lung Cancer
    Dr. Tannir is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Lymphofollicular Hyperplasia
    Dr. Tannir is
    Experienced
    . Learn about Lymphofollicular Hyperplasia.
    See more Lymphofollicular Hyperplasia experts
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved